Details of the Drug

General Information of Drug (ID: DMENFD6)

Drug Name
Metelimumab
Synonyms CAT-192; SL15A-IgG4; Anti-TGF beta 1 antibodies, Genzyme General/Cambridge Antibody Technologies
Indication
Disease Entry ICD 11 Status REF
Scleroderma 4A42 Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
UNII
4AR6718OL0
DrugBank ID
DB18695
TTD ID
D06FAA

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TGF-beta receptor type I (TGFBR1) TTP4520 TGFR1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Scleroderma
ICD Disease Classification 4A42
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TGF-beta receptor type I (TGFBR1) DTT TGFBR1 2.62E-01 0.27 1.01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00043706) Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis. U.S. National Institutes of Health.
2 Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.